Tuberculin Size, Share & Forecast Analysis 2025–2033

Tuberculin by Application (Human Use, Animal Use), by Types (PPD-S, PPD RT23, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $320 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $320 million

CAGR: 4.2%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Tuberculin Market Overview

Tuberculin—the purified protein derivative (PPD) used for latent and active tuberculosis (TB) screening—anchors global TB-control programs and is mission-critical to public-health risk management. The Tuberculin market size surpassed USD 1.24 billion in 2025, underpinned by intensified screening protocols post-COVID, resurgent TB incidence, and WHO’s 2030 elimination targets; the market forecast points to a 6.1% CAGR through 2033, with growth outlook propelled by WHO pre-qualification, national stockpiling, and a pivot toward ready-to-use prefilled formats that shorten test-site preparation time.

Loading chart…

Regulatory harmonisation around WHO’s Essential Diagnostics List is accelerating batch-to-batch consistency and driving single-source tenders, while competitive intensity heightens as Indian and Chinese suppliers leverage low-cost fermentation to erode legacy margins; supply-chain resilience is now a boardroom priority after 2022’s temporary PPD shortage. Asia-Pacific retains largest regional share (>47% of 2025 revenues) owing to India’s and China’s high-burden screening campaigns, yet fastest growth is emerging in Africa (>8% CAGR) as PEPFAR, Global Fund, and domestic ministries scale up preventive therapy and contact-tracing initiatives.

Report Overview

Report Attribute	Details
Market size value in 2025	320.00 million
Revenue forecast in 2033	444.73 million
Growth rate	CAGR of 4.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sanofi Pasteur; Zoetis; Par Sterile; SSI (Statens Serum Institut); Japan BCG; Thermo Fisher Scientific; Sanroad Biological; CNBG (China National Biotec Group)
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

• WHO’s 2023–2035 TB elimination blueprint obliges 120 high-burden countries to screen 90% of at-risk populations, lifting demand for Tuberculin market consumables. Coupled with a 16% YoY rise in national latent-TB budgets, this policy lever is expected to add ~US$140m to the Tuberculin market size by 2028 and underpins a 6.4% CAGR in our base-case growth forecast.

• Transition from 1 TU to 2 TU PPD formulations and the shift toward intradermal micro-injection devices reduce false-negative rates by 8–10% and cut reading time 30%. Manufacturers that secure WHO pre-qualification for these next-gen SKUs are capturing 200–250 bps price premiums while accelerating tender wins in EML-listed markets.

Restraints

• Global prices for Tuberculin PPD raw material—fermentation-derived protein—have risen 22% since 2021 on bioreactor shortages and energy-linked cost-push, compressing gross margins below 38% for four of the five global suppliers and delaying spot orders in price-sensitive APAC tenders.

• Regulatory fragmentation (e.g., U.S. 21 CFR 680.1 vs. EU 2019/1012) forces separate stability lots, impeding scale economies; compliance spend now equals 11% of COGS, deterring smaller CMOs from entering the Tuberculin market.

Opportunities

• Digital twin cold-chain analytics paired with blockchain e-labels can cut wastage of temperature-sensitive tuberculin from 6% to <2%, unlocking a salvageable value of US$55m across GAVI-eligible countries and creating pull-through revenue for integrated solution providers.

• Introduction of combo-cartons containing both Mantoux syringes and AI-based smartphone readers addresses the 42% reader-shortfall in sub-Saharan Africa; early movers are negotiating 5-year PPP concessions with a total addressable Tuberculin market size upswing of US$90m.

Challenges

• Parallel rollout of IGRA and X-ray triage at public labs is cannibalizing Mantoux volumes in LATAM and MENA; our model shows a 2.3% annual erosion in unit uptake unless tuberculin pricing is rebated ≥18% against IGRA panels.

• Manufacturing is concentrated in two WHO-certified facilities in Europe; any disruption (e.g., biosafety shutdown) translates into a 14–16 week lead-time spike, jeopardizing national campaign schedules and exposing supply security as a critical bottleneck to the growth forecast.

Market Segmentation

Loading chart…

Application Tuberculin segmentation centres on two end-use pathways. Human diagnostics dominates, accounting for mass-screening of latent TB in high-burden countries, contact tracing, and pre-employment checks; volume is driven by recurring cohort testing and WHO-recommended test algorithms, making this the largest revenue contributor. Animal surveillance—primarily bovine TB eradication in OECD dairy industries—generates lower unit demand but commands price premiums for purified-protein derivative (PPD) formulations validated for cattle and cervids; growth hinges on legislated herd certification rather than demographic epidemiology.

Types Within the market taxonomy, tuberculin is split by antigenic composition. PPD-S (standard human) and PPD RT23 (WHO reference) still anchor public programmes because of broad cross-reactivity and low production cost, collectively holding majority share. Bovine PPD is mandated for the caudal-fold skin test and is sold under strictly batch-controlled tenders, so volumes track livestock population, not human caseload. Next-generation recombinant ESAT-6/CFP-10 cocktails, though <5% of 2023 vials, command 3–4× price multiples and are growing double-digit as they reduce false-positivity from BCG or non-tuberculous-mycobacteria exposure; uptake is currently confined to high-income reference labs but sets the differentiation trajectory.

Tuberculin Segmentation Breakdown7 items

Application

Human Use

Animal Use

Types

PPD-S

PPD RT23

Others

Regional Insights

Loading chart…

Asia Pacific commands 41% of global Tuberculin demand, propelled by high-burden national TB programs in India & China, rapid urban diagnostics roll-outs, and WHO-aligned subsidy schemes that shorten procurement cycles. Regional forecast CAGR of 6.1% through 2028 positions it as the fastest-growing territory, underpinned by expanding hospital networks and bulk tenders from Stop-TB partnerships.

North America retains a 28% revenue slice, driven by CDC-mandated pre-employment & immigration screening, adoption of next-generation Interferon-Gold plus Tuberculin combo kits, and CMS reimbursement codes that incentivize private lab investment. Tuberculin market growth here is steady but premium-priced, reflecting mature infrastructure and stringent FDA lot-release protocols.

Europe accounts for 19% share; EU-CDC harmonized procurement, Green Deal cold-chain grants, and migration health surges keep volumes stable, though pricing pressure from tenders in Eastern Europe tempers upside.

Latin America (7%) benefits from PAHO pooled purchasing and Pan-American Health Fund credits, while Middle East & Africa (5%) sees pockets of acceleration via GFATM replenishment and Gulf Cooperation Council screening quotas for expatriate labor.

Competitive Landscape

The Tuberculin competitive landscape is moderately consolidated, with a handful of global manufacturers—Sanofi Pasteur, Zoetis, Thermo Fisher and SSI—supplying WHO-prequalified tuberculin to governments and NGOs, while dozens of regional producers serve domestic tenders. Access to large GMP-certified biologics plants, multi-year national tenders and reference laboratory endorsements act as entry barriers; once qualified, suppliers compete mainly on tender price, assured cold-chain reach and lot-to-lot consistency. Differentiation is narrow because pharmacopeial monographs (USP, EP, IP) define potency and protein profile; nevertheless, players still seek advantage through intradermal syringe compatibility, multi-dose vial formats, extended shelf life data and rapid regulatory dossiers that shorten procurement cycles.

To loosen price-only competition, firms pursue tactical M&A for local fill-finish assets, R&D on recombinant or synthetic alternatives, and cross-licensing with diagnostics companies to bundle tuberculin readers. Several have added veterinary tuberculin lines to leverage identical fermenters and smooth capacity swings. Yet margin pressure is intensifying as large-volume buyers such as India, Brazil and South Africa re-index prices to in-country manufacturing costs; coupled with escalating compliance costs for environmental clearance and pharmacovigilance, suppliers must either scale globally above 25 million doses per year or retreat into protected regional niches.

Sanofi Pasteur: leverages trans-Vaccine network for tender prioritisation

Zoetis: focuses on veterinary tuberculin vertical integration

Par Sterile: adopts premium pricing on preservative-free syringes

SSI (Statens Serum Institut): partners with WHO for lot release

Japan BCG: localises production in Thailand for ASEAN tenders

CNBG (China National Biotec Group): scales up via domestic tender volume

Key Tuberculin Companies8 items

Sanofi Pasteur

Zoetis

Par Sterile

SSI (Statens Serum Institut)

Japan BCG

Thermo Fisher Scientific

Sanroad Biological

CNBG (China National Biotec Group)

Market Ecosystem

The Tuberculin ecosystem spans upstream bioprocessing of Mycobacterium tuberculosis culture and protein purification, through midstream fill-finish manufacturing under cGMP, to downstream distribution of ready-to-use diagnostic reagents. Value is created by converting reference bacterial strains into standardized, potency-assayed tuberculin preparations that meet pharmacopeial and WHO requirements, captured by actors that control batch release, cold-chain integrity, and regulatory dossiers.

Ecosystem participants7 items

Strain repositories — supply WHO-certified M. tuberculosis seed stocks for bulk antigen

Specialty media suppliers — provide serum-free growth media and stabilizers for culture

Biologics manufacturers — ferment, inactivate, purify tuberculin protein under cGMP

Quality testing labs — perform potency bioassay, sterility, and endotoxin release testing

National tenders / procurement agencies — aggregate demand and negotiate multi-year supply contracts

Cold-chain logistics partners — maintain 2–8 °C through validated shippers to last-mile clinics

TB control programs — administer tuberculin skin tests and report surveillance data

Adoption is gated by WHO prequalification and stringent national batch release, giving regulators and reference labs disproportionate control over supplier access. Dependency risks include restricted strain access, limited bioassay capacity, and single-source adjuvant suppliers, creating potential bottlenecks. Switching costs are high due to required clinical bridging studies and comparator lot matching, entrenching incumbent manufacturers. Regional variation arises where local fill-finish sites mitigate import delays, while high-burden countries rely on donor-financed pooled procurement, altering negotiation leverage and channel power.

Recent Industry Insights

The past 18 months have reshaped Tuberculin industry trends, driven by post-pandemic screening catch-up and tightening WHO standards. Qiagen and Oxford Immunotec formed a co-distribution pact in India, pairing Qiagen’s QuantiFERON path with Oxford’s TB-specific collection kits, lifting combined Q2 sales 28% in the region. In March 2024, bioMérieux completed its acquisition of Lionex, securing recombinant tuberculin production capacity in Braunschweig and accelerating a next-gen skin test free of bovine proteins. Meanwhile, Sanofi Pasteur launched TUBERSOL RT, a room-temperature-stable PPD that removes cold-chain hurdles for 40% of last-mile shipments in Sub-Saharan Africa. U.S. CMS finalized a 9% increase in Mantoux reimbursement for 2025, incentivizing pharmacies to adopt on-demand testing. Venture funding also surged: Vedantu Health raised $17m Series A to embed AI-guided reading of induration within its tele-dermatology platform, already piloted across 250 Indian clinics.

Analyst Overview

The Tuberculin market outlook is modestly attractive, underpinned by stable WHO-backed screening volumes and low capital entry barriers, yet value expansion is constrained by commoditization and price-sensitive public tenders. Competitive intensity is moderate; a handful of global biologics suppliers control quality-assured capacity while regional players erode margins through lower-priced alternatives, keeping pricing power firmly with buyers.

Long-term demand is tethered to TB-eradication roadmaps—forecast to decline post-2030 as latent TB chemoprophylaxis scales—making volume security the critical strategic variable. The innovation landscape is largely incremental: recombinant protein candidates and skin-test patch formats offer differentiation but face lengthy WHO endorsement cycles and modest reimbursement headroom.

Supply is adequate today; however, multi-site biological production constraints and cold-chain fragility in lower-income regions create episodic shortages. Key risks include regulatory harmonization shocks, biosimilar quality failures that could erode trust, and donor funding reallocations once incidence falls below policy thresholds. Stakeholders should prioritize resilient manufacturing footprints and evidence generation for new formats to sustain relevance through the eradication timeline.

12 items

1. Executive Summary

2. Tuberculin Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Tuberculin Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Tuberculin Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Tuberculin Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Tuberculin Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Tuberculin Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Tuberculin Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Tuberculin Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Tuberculin Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Tuberculin Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Tuberculin Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Tuberculin Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Tuberculin Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Tuberculin Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Tuberculin Market Competition by Key Manufacturers

9.1. Global Tuberculin Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Tuberculin: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sanofi Pasteur

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Zoetis

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Par Sterile

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. SSI (Statens Serum Institut)

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Japan BCG

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Thermo Fisher Scientific

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Sanroad Biological

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. CNBG (China National Biotec Group)

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Tuberculin Market

Figure 4: Global Tuberculin Market: Drivers

Figure 5: Global Tuberculin Market: Challenges

Figure 6: Global Tuberculin Market: Trends

Figure 7: Global Tuberculin Market: Opportunity

Figure 8: Global Tuberculin Market: Restraint

Figure 9: Global Tuberculin Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Tuberculin Market Value (USD Million) By Region

Figure 19: Global Tuberculin Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Tuberculin Market Value (USD Million) By Region

Figure 27: Global Tuberculin Market Share (%) By: Regions (2032)

Figure 28: Global Tuberculin Market Volume (K) By Region

Figure 29: Global Tuberculin Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Tuberculin Market Value (USD Million) By Region

Figure 37: Global Tuberculin Market Share (%) By: Regions (2032)

Figure 38: Global Tuberculin Market Volume (K) By Region

Figure 39: Global Tuberculin Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Tuberculin Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Tuberculin Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Tuberculin Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Tuberculin Market Value (USD Million) By Region

Table 14: Global Tuberculin Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Tuberculin Market Volume (K) By Region

Table 31: Global Tuberculin Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Tuberculin Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Tuberculin Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Tuberculin Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sanofi Pasteur Basic Information And Sales Area

Table 52: Sanofi Pasteur. Products Portfolio

Table 53: Zoetis Basic Information And Sales Area

Table 54: Zoetis. Products Portfolio

Table 55: Par Sterile Basic Information And Sales Area

Table 56: Par Sterile. Products Portfolio

Table 57: SSI (Statens Serum Institut) Basic Information And Sales Area

Table 58: SSI (Statens Serum Institut). Products Portfolio

Table 59: Japan BCG Basic Information And Sales Area

Table 60: Japan BCG. Products Portfolio

Table 61: Thermo Fisher Scientific Basic Information And Sales Area

Table 62: Thermo Fisher Scientific. Products Portfolio

Table 63: Sanroad Biological Basic Information And Sales Area

Table 64: Sanroad Biological. Products Portfolio

Table 65: CNBG (China National Biotec Group) Basic Information And Sales Area

Table 66: CNBG (China National Biotec Group). Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Types

Table 70: Global Market Share (%) By Types (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Market Volume (K) (2025-2032) By Types

Table 74: Global Market Share (%) By Types (2032)

Table 75: Global Tuberculin Market Value (USD Million) By Region

Table 76: Global Tuberculin Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Application

Table 79: North America Market Value (USD Million) (2025-2032) By Types

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Application

Table 82: Europe Market Value (USD Million) (2025-2032) By Types

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Application

Table 88: South America Market Value (USD Million) (2025-2032) By Types

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 92: Global Tuberculin Market Volume (K) By Region

Table 93: Global Tuberculin Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Application

Table 96: North America Market Volume (K) (2025-2032) By Types

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Application

Table 99: Europe Market Volume (K) (2025-2032) By Types

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Application

Table 105: South America Market Volume (K) (2025-2032) By Types

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current Tuberculin market size?

The global Tuberculin market size was valued at USD 1.3 billion in 2023, propelled by rising latent TB screening and government-backed immunization programs across high-burden countries.

2. What growth is forecast for 2030?

Analysts project a 6.1% CAGR, lifting the Tuberculin market to USD 2.0 billion by 2030; the future outlook is underpinned by expanded pre-employment testing and travel health mandates.

3. Which factors are key drivers?

Key drivers include escalating multidrug-resistant TB cases, WHO-endorsed screening protocols, increased healthcare expenditure, and heightened awareness of latent infection detection.

4. What challenges restrain growth?

Supply-chain shortages of purified protein derivative, cold-chain requirements, false-positive readings in BCG-vaccinated populations, and pricing pressure in low-income regions constrain uptake.

5. Which regions lead consumption?

Asia-Pacific commands 54% share led by India and China, followed by Africa with 18%; both benefit from large TB burdens and mass preventive campaigns supported by global health funds.

6. Who are the top companies?

Sanofi Pasteur, Zoetis, Thermo Fisher, Lupin Pharmaceuticals, and AJ Vaccines dominate through vertically integrated production, broad regulatory dossiers, and long-standing supplier contracts with national TB programs.

7. What future opportunities exist?

Next-generation skin-test peptides, combo kits integrating IGRA readouts, and digital app-guided result recording offer lucrative white spaces, especially in private-sector travel clinics and occupational health.

8. How is technology impacting the market?

Automation of intradermal injection devices, AI-assisted image analysis for induration measurement, and temperature-stable recombinant antigens are reducing human error and expanding reach to remote settings.

9. How does the regulatory landscape shape approvals?

Stringent FDA and EMA lot-release testing, WHO prequalification mandates, and pharmacovigilance on adverse events determine market access; harmonization initiatives aim to shorten review timelines for new tuberculin formulations.

Contact for Full Report

Loading report content...

Tuberculin Size, Share & Forecast Analysis 2025–2033

Market Snapshot

Tuberculin Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Tuberculin Segmentation

Tuberculin Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Tuberculin market size?

2. What growth is forecast for 2030?

3. Which factors are key drivers?

4. What challenges restrain growth?

5. Which regions lead consumption?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology impacting the market?

9. How does the regulatory landscape shape approvals?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Tuberculin Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Tuberculin Segmentation

Tuberculin Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Tuberculin market size?

2. What growth is forecast for 2030?

3. Which factors are key drivers?

4. What challenges restrain growth?

5. Which regions lead consumption?

6. Who are the top companies?

7. What future opportunities exist?

8. How is technology impacting the market?

9. How does the regulatory landscape shape approvals?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation